Shades Of Prasugrel: Brilinta Review Felt The Effects Of Effient’s Experience
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA’s review of AstraZeneca’s platelet inhibitor ticagrelor was tinged by the agency’s earlier evaluation and delayed approval of Lilly/Daiichi’s prasugrel for acute coronary syndromes.